Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007340
Chunk: 108

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 108
---
     |                    |   140,820,000 |     |            |   * |   |
| Ladenburg Thalmann & Co., Inc. (14)            |     |                    |   202,750,000 |     |                   |  25,830,000 |     |                    |   176,920,000 |     |            |   * |   |
| Nicholas Stergis (15)                          |     |                    |    74,490,000 |     |                   |  32,280,000 |     |                    |    42,210,000 |     |            |   * |   |
| David Coherd (16)                              |     |                    |     9,630,000 |     |                   |   4,520,000 |     |                    |     5,110,000 |     |            |   * |   |
| Mark Weinberger (17)                           |     |                    |     3,200,000 |     |                   |   1,930,000 |     |                    |     1,270,000 |     |            |   * |   |

____________

* Represents beneficial ownership of less than 1%.

**Subject to beneficial ownership blocker.

*** Based upon 25,617,408,922 Ordinary Shares issued and outstanding
as of April 1, 2025.

| 60 |

| (1) | Assumes that all Ordinary Shares being registered under the registration                                                                
 statement of which this prospectus forms a part are sold in this offering, and that none of the selling stockholders acquire additional 
 Ordinary Shares after the date of this prospectus and prior to completion of this offering. The information set forth in the footnotes  
 is based upon our information and belief, the records of the Company and the selling stockholder’s filing with the SEC, if any.         |

| (2) | The selling shareholder holds (i) warrants issued by us in prior                                                                              
 transactions which entitle the selling shareholder to purchase an aggregate of 518,720,000 Ordinary Shares (in the form of Depositary         
 Shares), and (ii) Replacement Warrants issued by us which entitle the selling shareholder to purchase an aggregate of 324,740,000 Ordinary    
 Shares (in the form of Depositary Shares) and which we are registering hereby. The warrants are subject to a beneficial ownership limitation  
 of 9.99%, which does not permit the selling shareholder